![[Functional and Stereotactic Neurosurgery]](/images/INRadhome8.JPG) ![[Cerebrovascular Surgery Center]](/images/VASChome8.JPG) |
Interventional
Neuroradiology
Endovascular Treatment of Cerebral Vasospasm |
The
Interventional Neuroradiology service at Massachusetts General
Hospital
and the MGH Brain Aneurysm & AVM Center. |
Cerebral vasospasm remains a significant causing of death and disability
among patients surviving subarachnoid hemorrhage from cerebral aneurysms.
Advancements in medical therapy, including prophylactic calcium
channel blockers and "triple-H" therapy (hemodilution,
hypervolemia and hypertension) and bedside transcranial doppler
have significantly improved our ability to deal with this dreaded
complication of subarachnoid hemorrhage. In spite of compulsive
ICU care and early institution of hemodynamic augmentation, some
patients continue to decline neurologically from ischemia induced
by cerebral vasospasm. In such cases, one should quickly proceed
to consider endovascular therapy after excluding confounding problems
such as infection, hydrocephalus and aneurysm re-rupture. One has
the highest chance of averting stroke with early intervention. Ideally,
one should initiate endovascular alternatives following a failed
6-12 hour trial of "triple-H" therapy.
Marked advances in instrumentation
over the last decade have led to the development of several endovascular
strategies to treat vasospasm. Transluminal balloon angioplasty
was demonstrated to be efficacious in carefully selected patients
with large vessel spasm (Zubkov, 1984). Since then, advancements
in balloon and catheter technologies have made this technique
more widely applicable and much safer. For example, the original
balloons used were relatively stiff latex balloons. Soft, silicone
balloons became available in the late 1980's, and they have dramatically
reduced the risk of catastrophic vessel rupture. More recently,
promising over-the-wire silicone balloon microcatheter systems
have been introduced. Angioplasty of smaller vessels is known
to be particularly hazardous, but these over-the-wire systems
may allow a wider application of angioplasty techniques, particularly
to the A1 and proximal M2.
Angioplasty is performed via a
femoral artery approach, usually with a 6 or 7 French sheath.
Ideally, the ruptured aneurysm is secured prior to angioplasty.
Systemic heparinization is used to minimize the risk of thromboembolic
events. Most patients are not able to cooperate for the procedure
and it is best performed under general anesthesia. Only areas
of vasospasm which correlate with symptoms should be targeted
for treatment. This may change with the advent of imaging techniques
capable of detecting sub-clinical ischemia.
A number of reasonably large series
reporting the results of balloon angioplasty for the treatment
of cerebral vasospasm after subarachnoid hemorrhage are now available
in the literature (Brothers 1990, Takahashi, 1990, Higashida 1992,
Eskridge 1994). The angiographic efficacy has been shown to be
extremely high: 98-100% in most series. Clinical improvement has
been noted in 65-70% of cases. Good results have been found to
correlate with early and aggressive intervention after the failure
of medical ("triple-H") therapy. Some authors suggest
a temporal window of opportunity of 6-12 hours.
Reported complications resulting
from balloon angioplasty for cerebral vasospasm following subarachnoid
hemorrhage include perforation, aneurysm re-rupture, branch occlusion
and hemorrhagic infarct. The complication rates are probably underestimated
in the literature. Vessel rupture is reported in 2-5% of cases,
rebleed from unclipped aneurysms is found in roughly 5% of cases.
Importantly, the effect of angioplasty in the setting of cerebral
vasospasm has been found to be lasting, and re-treatments are
rarely, if ever, needed.
Another endovascular treatment
strategy for vasospasm is intra-arterial infusion of papaverine.
Papaverine is an alkaloid compound and is a powerful vasodilator.
It acts directly on the smooth muscle cells of the arterial wall
by trans-endothelial absorption. Favorable results in treating
patients have also been reported with very low complication rates
(Kaku 1992, Kassell 1992, Clouston 1995). Typically, papaverine
is infused as a concentration of 3 mg/ml at 6-9 ml/min for a total
dose of up to 300 mg per vascular territory. Since the absorption
is trans-endothelial, it is not surprising that the best results
have been obtained with an infusion close to the site of spasm.
Because of reported ocular complications, a supra-ophthalmic position
should be used if at all possible. An angiographic response is
seen in 80-95% of cases. A clinical response is seen in 25-50%
of cases.
As with angioplasty, the ruptured
aneurysm is ideally secured prior to treatment and systemic heparinization
is used routinely. The primary advantage of papaverine is its
ability to treat distal spasm not safely approached with an angioplasty
balloon. The main drawback of this form of therapy is its transient
effect (24-48 hours). This typically necessitates multiple treatments,
even as high as 6 to 8 in any given patient. The potential adverse
effects of papaverine which have been reported include transient
neurologic dysfunction, seizure, mydriasis, monoccular blindness,
drug precipitation, increased intracranial pressure and even aggravation
of spasm (Clyde 1996). Of these, by far the most common and troublesome
in our experience is elevation of the intracranial pressure. Fortunately,
this can usually be controlled (<20 mm H20) with a mannitol infusion
(25-50 gm). However, on occasion, the infusion must be either
slowed or even stopped. Other complications which can occur with
this form of treatment include dissection and thromboembolism.
The rate of serious complications is in the range of 5% or less
of patients.
Balloon angioplasty and intra-arterial
papaverine infusion should be viewed as complimentary approaches
to the treatment of cerebral vasospasm. Both should be offered
as soon as possible after the patient demonstrates a neurologic
decline unresponsive to medical therapy. Probably, the most reasonable
approach is to alleviate proximal, symptomatic spasm with angioplasty
and proceed with papaverine infusion if there remains severe distal
spasm. This approach has been reported to achieve good results
(Kaku 1992).
References:
- Brothers MF, Holgate RC, Intracranial
angioplasty for treatment of vasospasm after subarachnoid hemorrhage:
technique and modifications to improve branch access. AJNR 11:239-247,
(1990).
- Clouston JE. Numaguchi Y. Zoarski
GH. Aldrich EF. Simard JM. Zitnay KM. Intraarterial papaverine
infusion for cerebral vasospasm after subarachnoid hemorrhage.
AJNR. 16(1):27-38, (1995).
- Clyde BL, Firlik AD, Kaufmann
AM, Spearman MP, Yonas H. Paradoxical aggravation of vasospasm
with papaverine infusion following aneurysmal subarachnoid hemorrhage:
case report. J Neurosurg, 84:690-695 (1996).
- Eskridge JM, Newell DW, Mayberg
MR, Winn HR. Update on transluminal angioplasty of vasospasm.
Perspect Neurol Surg 1:120-126 (1990).
- Eskridge JM, Newell DW, Winn HR.
Endovascular treatment of vasospasm. Neurosurg Clin N Am 5:
437-47 (1994)
- Higashida RT, Halbach VV, Dowd
CF, et al Intravascular balloon dilatation therapy for intracranial
arterial vasospasm: patient selection, technique and clinical
results. Neurosurg Rev 15:89-95 (1992).
- Kaku Y. Yonekawa Y. Tsukahara
T. Kazekawa K. Superselective intra-arterial infusion of papaverine
for the treatment of cerebral vasospasm after subarachnoid hemorrhage.
J Neurosurg 77(6):842-7, (1992).
- Kallmes DF. Jensen ME. Dion JE.
Infusing doubt into the efficacy of papaverine. AJNR. 18(2):263-4,
(1997).
- Kassell NF. Helm G. Simmons N.
Phillips CD. Cail WS. Treatment of cerebral vasospasm with intra-arterial
papaverine. J Neurosurg 77(6):848-52, (1992).
- Livingston K. Guterman LR. Hopkins
LN. Intraarterial papaverine as an adjunct to transluminal angioplasty
for vasospasm induced by subarachnoid Am J Neuroradiol. 14(2):346-7,
(1993).
- Marks MP. Steinberg GK. Lane B.
Intraarterial papaverine for the treatment of vasospasm. AJNR.
14(4):822-6, (1993).
- Mathis JM. DeNardo A. Jensen ME.
Scott J. Dion JE. Transient neurologic events associated with
intraarterial papaverine infusion for subarachnoid hemorrhage-induced
vasospasm. AJNR 15(9):1671-4, (1994).
- Mathis JM. Jensen ME. Dion JE.
Technical considerations on intra-arterial papaverine hydrochloride
for cerebral vasospasm. Neuroradiology. 39(2):90-8, (1997).
- McAuliffe W, Townsend M, Eskridge
JM, Newell DW, Grady S, Winn HR, Intracranial pressure changes
induced during papaverine infusion for treatment of vasospasm.
J Neurosurg 83:430-434 (1995).
- Takahashi A, Yoshoto T, Mizoi
K, et al, Transluminal balloon angioplasty for vasospasm after
subarachnoid hemorrhage. In: Cerebral Vasspam, edited by K Sano,
K Takakura, NF Kassell and T Sasaki, pp. 429-432, U Tokyo Press,
Tokyo, 1990.
- Tsukahara T. Yoshimura S. Kazekawa
K. Hashimoto N. Intra-arterial papaverine for the treatment
of cerebral vasospasm after subarachnoid hemorrhage. Autonomic
Nervous System. 49 Suppl:S163-6, (1994).
- Zubkov YN, Nikiforov BM, Shustin
VA, Balloon catheter technique for dilatation ofconstricted
cerebral arteries after aneurysmal SAH. Acta Neurochir (Wien),
70:65-79, (1984).
|